273 related articles for article (PubMed ID: 30347454)
1. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.
Chu X; Liao M; Shen H; Yoshida K; Zur AA; Arya V; Galetin A; Giacomini KM; Hanna I; Kusuhara H; Lai Y; Rodrigues D; Sugiyama Y; Zamek-Gliszczynski MJ; Zhang L;
Clin Pharmacol Ther; 2018 Nov; 104(5):836-864. PubMed ID: 30347454
[TBL] [Abstract][Full Text] [Related]
2. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.
Zamek-Gliszczynski MJ; Taub ME; Chothe PP; Chu X; Giacomini KM; Kim RB; Ray AS; Stocker SL; Unadkat JD; Wittwer MB; Xia C; Yee SW; Zhang L; Zhang Y;
Clin Pharmacol Ther; 2018 Nov; 104(5):890-899. PubMed ID: 30091177
[TBL] [Abstract][Full Text] [Related]
3. The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development.
Giacomini KM; Galetin A; Huang SM
Clin Pharmacol Ther; 2018 Nov; 104(5):766-771. PubMed ID: 30137696
[No Abstract] [Full Text] [Related]
4. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.
Evers R; Piquette-Miller M; Polli JW; Russel FGM; Sprowl JA; Tohyama K; Ware JA; de Wildt SN; Xie W; Brouwer KLR;
Clin Pharmacol Ther; 2018 Nov; 104(5):900-915. PubMed ID: 29756222
[TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.
Schlessinger A; Welch MA; van Vlijmen H; Korzekwa K; Swaan PW; Matsson P
Clin Pharmacol Ther; 2018 Nov; 104(5):818-835. PubMed ID: 29981151
[TBL] [Abstract][Full Text] [Related]
6. Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes.
Mariappan TT; Shen H; Marathe P
Curr Drug Metab; 2017 Oct; 18(8):757-768. PubMed ID: 28738769
[TBL] [Abstract][Full Text] [Related]
7. Transporters in Drug Development: Scientific and Regulatory Considerations.
Zhang L; Huang SM; Reynolds K; Madabushi R; Zineh I
Clin Pharmacol Ther; 2018 Nov; 104(5):793-796. PubMed ID: 30270426
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
Momper JD; Tsunoda SM; Ma JD
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
[TBL] [Abstract][Full Text] [Related]
9. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
[TBL] [Abstract][Full Text] [Related]
11. Progress in the Quantitative Assessment of Transporter-Mediated Drug-Drug Interactions Using Endogenous Substrates in Clinical Studies.
Mochizuki T; Kusuhara H
Drug Metab Dispos; 2023 Sep; 51(9):1105-1113. PubMed ID: 37169512
[TBL] [Abstract][Full Text] [Related]
12. Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation.
Li Y; Talebi Z; Chen X; Sparreboom A; Hu S
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576971
[TBL] [Abstract][Full Text] [Related]
13. Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific Perspective.
Arya V; Reynolds KS; Yang X
J Clin Pharmacol; 2022 Dec; 62(12):1501-1506. PubMed ID: 35778968
[TBL] [Abstract][Full Text] [Related]
14. Transporters and drug-drug interactions: important determinants of drug disposition and effects.
König J; Müller F; Fromm MF
Pharmacol Rev; 2013 Jul; 65(3):944-66. PubMed ID: 23686349
[TBL] [Abstract][Full Text] [Related]
15. Studying the right transporter at the right time: an
Elsby R; Atkinson H; Butler P; Riley RJ
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):619-655. PubMed ID: 36205497
[TBL] [Abstract][Full Text] [Related]
16. In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.
Yoshida K; Zhao P; Zhang L; Abernethy DR; Rekić D; Reynolds KS; Galetin A; Huang SM
J Pharm Sci; 2017 Sep; 106(9):2209-2213. PubMed ID: 28456729
[TBL] [Abstract][Full Text] [Related]
17. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.
Mochizuki T; Mizuno T; Maeda K; Kusuhara H
Drug Metab Pharmacokinet; 2021 Apr; 37():100358. PubMed ID: 33461054
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.
Fuhr U; Hsin CH; Li X; Jabrane W; Sörgel F
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():507-536. PubMed ID: 30156973
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for In Vivo Assessment of Transporter Function.
Müller F; Sharma A; König J; Fromm MF
Pharmacol Rev; 2018 Apr; 70(2):246-277. PubMed ID: 29487084
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions.
Maeda K
Drug Metab Pharmacokinet; 2020 Feb; 35(1):76-88. PubMed ID: 31948854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
